Olanzapine in the Treatment of Hair Pulling (Trichotillomania)
A 12-Week, Double-Blind Trial of Olanzapine and Placebo in the Treatment of Trichotillomania
1 other identifier
interventional
34
1 country
1
Brief Summary
Trichotillomania (TTM) or hair-pulling has been considered as part of the obsessive compulsive disorder (OCD) spectrum, although treatment with OCD medications has largely been unsuccessful. Tics/Tourrettes' Syndrome (TS) is a disorder, which appears to be related to TTM, but is treated with a different class of medications than used in OCD, namely antipsychotics such as olanzapine. This is a study of the safety and efficacy of olanzapine in the treatment of hair pulling.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at below P25 for phase_4
Started Jun 2000
Longer than P75 for phase_4
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
June 1, 2000
CompletedFirst Submitted
Initial submission to the registry
September 14, 2005
CompletedFirst Posted
Study publicly available on registry
September 16, 2005
CompletedStudy Completion
Last participant's last visit for all outcomes
March 1, 2006
CompletedSeptember 11, 2006
March 1, 2006
September 14, 2005
September 8, 2006
Conditions
Outcome Measures
Primary Outcomes (1)
Clinical Global Impression (CGI)-Improvement Scale ≤ 2
Secondary Outcomes (1)
CGI-Severity Scale, Mean change from baseline in: Yale-Brown Obsessive Compulsive Scale for TTM, the Massachusetts General Hospital Hair Pulling Scale
Interventions
Eligibility Criteria
You may qualify if:
- primary DSM-IV trichotillomania; CGI-Severity ≥ 4
You may not qualify if:
- Any other Axis I primary diagnosis; CGI-S \< 4; current comorbid: OCD, MDD, alcohol or substance abuse; lifetime hx of: schizophrenia, bipolar affective disorder or dementia; current pregnancy/lactation; current suicidality or homicidality; major medical problems or clinically unstable medical disease; hx of: seizures, stroke or head trauma; prior use of neuroleptics
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Hamilton Health Sciences Corporationlead
- Eli Lilly and Companycollaborator
Study Sites (1)
Hamilton Health Sciences, McMaster University Medical Centre
Hamilton, Ontario, L8N 3Z5, Canada
Related Publications (2)
Hoffman J, Williams T, Rothbart R, Ipser JC, Fineberg N, Chamberlain SR, Stein DJ. Pharmacotherapy for trichotillomania. Cochrane Database Syst Rev. 2021 Sep 28;9(9):CD007662. doi: 10.1002/14651858.CD007662.pub3.
PMID: 34582562DERIVEDVan Ameringen M, Mancini C, Patterson B, Bennett M, Oakman J. A randomized, double-blind, placebo-controlled trial of olanzapine in the treatment of trichotillomania. J Clin Psychiatry. 2010 Oct;71(10):1336-43. doi: 10.4088/JCP.09m05114gre. Epub 2010 Apr 20.
PMID: 20441724DERIVED
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Michael A Van Ameringen, MD, FRCPC
Hamilton Health Science, McMaster Univeristy Medical Centre
Study Design
- Study Type
- interventional
- Phase
- phase 4
- Allocation
- RANDOMIZED
- Masking
- DOUBLE
- Purpose
- TREATMENT
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
Study Record Dates
First Submitted
September 14, 2005
First Posted
September 16, 2005
Study Start
June 1, 2000
Study Completion
March 1, 2006
Last Updated
September 11, 2006
Record last verified: 2006-03